In vivo models for immuno-oncology research
In addition to general oncology study types and readouts, we offer a well-characterised portfolio of cell line-derived syngeneic immuno-oncology (IO) models, tailored to meet your research needs. Our models include comprehensive evaluation of major immune cell subsets, correlated with tumour progression. We utilise cell line-derived xenograft (CDX) syngeneic tumour models to study cancer therapies in the presence of a functional immune system. Additionally, we provide hPBMC/HSC/T-cell humanised models.
- Anti-tumor efficacy studies (including tolerability and exposure studies)
- Syngeneic CDX derived models
- Humanised mouse models (PBMCs, HSCs, T-cells)
- Pharmacokinetic (PK) and pharmacodynamic (PD) assessments
- In vivo imaging (bioluminescence, fluorescence)
- Cytokine and immuno-profiling employing spectral flow cytometry (>28 parameters)
- Single-cell RNA sequencing
- Profiling of tumor-infiltrating lymphocytes and immuno-modulation effects
- Single and multi-color fluorescent and chromogenic staining
- In situ hybridization (RNAscope).
